Dr Sarah Smith

  • MBBS, B Med Sci, MRCP, FRCR
  • Consultant Clinical Oncologist

Overview

Dr Sarah Smith is a Consultant Clinical Oncologist specialising in breast, rectal, ovarian and endometrial cancer treatment.

She leads on breast, rectal, ovarian and endometrial cancer treatment in Bedford Hospital and has opened multiple nationally-recognised trials for local patient participation. Clinical Director for Oncology and Palliative Care at Bedford Hospital. She also holds the position as Governance Lead at Addenbrookes Hospital.

Dr Smith obtained her medical degree from Imperial College School of Medicine, London, in 1998. During her training she also obtained her Bachelor of Medical Science at St Bartholomew’s and the Royal London School of Medicine in 1997.

After completing her general medical training, during which time she obtained her MRCP, she went onto the specialist registrar clinical oncology London training programme for five years. She worked at various London hospitals during this time, including University College Hospital, Mount Vernon Hospital and the Royal Marsden Hospital, and also obtained her FRCR. Dr Smith joined Bedford Hospital NHS Trust in 2008 as a Consultant Clinical Oncologist.

Her current position is split between working at Bedford and Addenbrookes Hospitals.

Clinical interests

Dr Smith has a special clinical interest in breast cancer; ovarian cancer; endometrial cancer; colorectal (bowel) cancer; radiotherapy simultaneous integrated boost; partial breast radiotherapy; heart sparing radiotherapy techniques; nodal radiotherapy for breast cancer; chemo-radiation; chemotherapy; radiotherapy; targeted therapy; endocrine therapy

Publications and affiliations

  1. Natural relief for persons receiving chemotherapy – focus on the Polybalm nail bed study. R Thomas. S Smith, S Berkovitz. International Journal of Clnical Aromatherapy 2018, vol.13, issue1 cancer and palliative care ISSN 1961-7623. Pp 2-8
  2. A double-blind, randomised trial of a polyphenolic-rich nail bed balm for chemotherapy-induced onycholysis: the UK polybalm study
  3. Identifying and preventing delays in the fast-track discharge process